French pharmaceutical company Mitem Pharma revealed on Tuesday that it has acquired the rights to Flisint (fumagillin) from Sanofi Winthrop Industrie, part of French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY), to ensure continued availability of the only treatment for Enterocytozoon bieneusi microsporidia infections.

These infections affect immunosuppressed patients, including those with AIDS or organ transplants, with no alternative treatment available.

Since Flisint was discontinued in 2019, the university hospital platform Fripharm has been producing it as a magistral preparation using Sanofi's remaining stock of the active ingredient. Mitem Pharma now aims to update and relaunch Flisint's manufacturing process at the request of Fripharm's team.

Flisint holds marketing authorisation in France and is in demand internationally, including in Europe, the United States, Argentina and Australia. This acquisition aligns with Mitem Pharma's strategy to provide essential medicines that have been withdrawn from the market.

Supported by the Techlife Capital investment fund, Mitem Pharma will leverage its expertise in Drugs of Major Therapeutic Interest and its commercial network across 60 countries to expand access to Flisint.